TY - JOUR
T1 - Protein kinases as drug targets in human and animal diseases
AU - Kini, Suvarna G.
AU - Garg, Vikas
AU - Prasanna, Sarada
AU - Rajappan, Revathi
AU - Mubeen, Muhammad
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Almost thirty percent of the protein targets currently under exploration and study constitute the protein kinases which have always attracted the pharmaceutical companies as they are easy targets for drug development. Although the kinases will remain major focus of oncology for many years to come in the development of anticancer drugs, the number of kinase inhibitors as therapeutic targets for the treatment of several other diseases which are undergoing clinical trials are exponentially increasin. In this review, we discuss very briefly the different types of protein kinases that have been used as targets for developing drugs for cancer, inflammation, autoimmune disease, heart disease andanimal diseases.
AB - Almost thirty percent of the protein targets currently under exploration and study constitute the protein kinases which have always attracted the pharmaceutical companies as they are easy targets for drug development. Although the kinases will remain major focus of oncology for many years to come in the development of anticancer drugs, the number of kinase inhibitors as therapeutic targets for the treatment of several other diseases which are undergoing clinical trials are exponentially increasin. In this review, we discuss very briefly the different types of protein kinases that have been used as targets for developing drugs for cancer, inflammation, autoimmune disease, heart disease andanimal diseases.
UR - http://www.scopus.com/inward/record.url?scp=85025138279&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85025138279&partnerID=8YFLogxK
U2 - 10.2174/1573408013666161128144216
DO - 10.2174/1573408013666161128144216
M3 - Review article
AN - SCOPUS:85025138279
SN - 1573-4080
VL - 13
SP - 99
EP - 106
JO - Current Enzyme Inhibition
JF - Current Enzyme Inhibition
IS - 2
ER -